| Autor: |
Levy, H. Roma, Bayer, Siming, Gurung, Arati, Stich, Manuel, Sotomayor, Jorge Rosado |
| Zdroj: |
Clinical Lab Products; Jul2024, Vol. 54 Issue 4, p30-35, 6p |
| Abstrakt: |
This article provides information on metabolic dysfunction-associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease (NAFLD). It highlights the global prevalence of MASLD and its association with overweight or obesity and cardiometabolic risk factors. The article emphasizes the importance of early recognition and diagnosis of MASLD to prevent severe complications such as liver transplantation and hepatocellular carcinoma. Non-invasive imaging techniques like ultrasound and magnetic resonance imaging are discussed as valuable tools for diagnosing and monitoring the disease. The article also mentions the Enhanced Liver Fibrosis (ELF) Test, the only FDA-approved test for prognostic risk assessment in liver fibrogenesis, and the importance of early detection and surveillance for MASLD and its more aggressive counterpart, metabolic-associated steatohepatitis (MASH). The need for non-invasive diagnostic tools and refined surveillance protocols is emphasized to address the challenges posed by MASLD and MASH. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
